NASDAQ · Biotechnology

PDSB (PDSB) Stock

$0.69 -0.64% NASDAQ: PDSB Healthcare

Valuation

MetricValue
Price$0.69
Market Cap$38.49M
P/E Ratio-1.39
P/B Ratio6.39
P/S Ratio0.00
EPS (TTM)$-0.74
52-Week High$1.66
52-Week Low$0.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-377.78%
ROA-113.33%
ROCE-355.56%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity1.35
Current Ratio3.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-42.0M$-43.0M$-36.0M$-32.0M
Net Profit$-17.0M$-41.0M$-43.0M$-38.0M$-34.0M
EPS$-0.66$-1.43$-1.39$-1.03$-0.74
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$67.0M$77.0M$59.0M$45.0M$30.0M
Total Liabilities$4.0M$33.0M$33.0M$26.0M$21.0M
Cash$65.0M$74.0M$57.0M$42.0M$27.0M
Borrowings$0$23.0M$24.0M$22.0M$5.2B

Latest News

Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher Zacks · Jun 10, 2026 PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... GuruFocus.com · May 13, 2026 PDS Biotechnology Q1 Earnings Call Highlights MarketBeat · May 13, 2026 PDS Biotechnology Corporation Q1 2026 Earnings Call Summary Moby · May 13, 2026 PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript Benzinga · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-26.0M$-34.0M$-35.0M$-27.8B
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$-1.0M$0$1.0M$12.8B
Net Cash Flow$36.0M$9.0M$-17.0M$-15.0M$-15.0B
Free Cash Flow$-12.0M$-26.0M$-34.0M$-35.0M$-27.8B

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-7636.73%
Quick Ratio2.26
Interest Coverage-6.40
Return 1Y-37.11%
Return 3Y-85.66%
Return 5Y-92.33%

Ownership

Insiders Held1.51%
Institutions Held9.17%
Institutions Float Held9.31%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,631,0892026-03-31
Geode Capital Management, LLC660,2282026-03-31
Blackrock Inc.554,0482026-03-31
Vanguard Fiduciary Trust Co307,3112026-03-31
BLAIR WILLIAM & CO/IL300,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%

About PDSB

PDSB is led by CEO Frank K. Bedu-Addo, employs 24 people, headquartered in US, publicly traded since 2015.

PDSB stock trades at $0.69 with a market capitalization of $38.49M. The stock is valued at a price-to-earnings (P/E) ratio of -1.39, price-to-book of 6.39, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.51 and $1.66, and currently trades 58.4% below its 52-week high.

On profitability, PDSB generates a return on equity (ROE) of -377.78%, return on capital employed of -355.56%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides